Daiichi Sankyo from Pharmafile, Pharmaceutical Executive - Journalist Profile

	Profile	Recent Articles on Subject
1	Daiichi Sankyo Pharmafile Global pharmaceutical company. Rich legacy. Tokyo, Japan pharmaceuticalsinnovation	Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment - about 1 year ago AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC - about 1 year ago Daiichi Sankyo, Merck Set to Collaborate on Three DXd Antibody-Drug Conjugates - about 1 year ago AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial - about 1 year ago
2	AstraZeneca Pharmafile	AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC - about 1 year ago AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial - about 1 year ago
3	Merck Pharmaceutical Executive	Daiichi Sankyo, Merck Set to Collaborate on Three DXd Antibody-Drug Conjugates - about 1 year ago